Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients

Maria Di Bartolomeo, Emilio Bajetta, Luisa Somma, Carlo Carnaghi, Elena Bandieri, Michele Del Vecchio, Corroda Gallo Stampino, Roberta Buzzoni

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The association of 5-fluorouracil (5-FU) and leucovorin is currently the most used combination in the treatment of advanced gastrointestinal neoplasms. Doxifluridine (d-FUR) is a fluoropyrimidine derivative that is converted into 5-FU inside tumor cells, where it is selectively cytotoxic. The oral administration of dFUR has been extensively investigated in colorectal carcinoma, and has been proven to be active and well tolerated. The purpose of this study was to test the effectiveness of the oral combination with dFUR plus I-leucovorin in gastric and pancreatic cancer patients. Methods: a total of 50 cases were treated with I-leucovorin 25 mg, followed 2 h later by d-FUR 1,200 mg/m2 for 5 days; the cycles were repeated every 10 days. The regimen was given for a maximum of 36 cycles or until disease progression. Twenty-six patients had gastric cancer (all of whom were pretreated with polychemotherapy) and 24 had advanced pancreatic carcinoma. Results: Objective responses were obtained in 4 (15%; 95% CI 1-29) patients with gastric cancer, and in I (4%) with pancreatic cancer. The median response duration was 4 months. All of the responses were seen in patients previously treated with 5-FU-containing regimens. The median survival in gastric cancer patients was 7 months. Toxicity was moderate: WHO grade III and IV diarrhea was observed in 14% of the cases. Conclusions: This study indicates the efficacy of oral d-FUR plus l-leucovorin as palliative treatment in gastric cancer patients. The results in Doxifluridine pancreatic carcinoma are disappointing but are in line with the published data Chemotherapy relating to fluoropyrimidines.

Original languageEnglish
Pages (from-to)54-57
Number of pages4
JournalOncology
Volume53
Issue number1
Publication statusPublished - Jan 1996

Fingerprint

Pancreatic Neoplasms
Palliative Care
Stomach Neoplasms
Leucovorin
Fluorouracil
Gastrointestinal Neoplasms
Combination Drug Therapy
Oral Administration
Disease Progression
doxifluridine
Colorectal Neoplasms
Diarrhea
Drug Therapy
Survival
Neoplasms

Keywords

  • Chemotherapy
  • Doxifluridine
  • Fluoropyrimidine
  • Gastric cancer
  • Pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. / Di Bartolomeo, Maria; Bajetta, Emilio; Somma, Luisa; Carnaghi, Carlo; Bandieri, Elena; Del Vecchio, Michele; Stampino, Corroda Gallo; Buzzoni, Roberta.

In: Oncology, Vol. 53, No. 1, 01.1996, p. 54-57.

Research output: Contribution to journalArticle

Di Bartolomeo, Maria ; Bajetta, Emilio ; Somma, Luisa ; Carnaghi, Carlo ; Bandieri, Elena ; Del Vecchio, Michele ; Stampino, Corroda Gallo ; Buzzoni, Roberta. / Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. In: Oncology. 1996 ; Vol. 53, No. 1. pp. 54-57.
@article{0d97b2e9774a458fad7eae3f07ffeb6b,
title = "Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients",
abstract = "Background: The association of 5-fluorouracil (5-FU) and leucovorin is currently the most used combination in the treatment of advanced gastrointestinal neoplasms. Doxifluridine (d-FUR) is a fluoropyrimidine derivative that is converted into 5-FU inside tumor cells, where it is selectively cytotoxic. The oral administration of dFUR has been extensively investigated in colorectal carcinoma, and has been proven to be active and well tolerated. The purpose of this study was to test the effectiveness of the oral combination with dFUR plus I-leucovorin in gastric and pancreatic cancer patients. Methods: a total of 50 cases were treated with I-leucovorin 25 mg, followed 2 h later by d-FUR 1,200 mg/m2 for 5 days; the cycles were repeated every 10 days. The regimen was given for a maximum of 36 cycles or until disease progression. Twenty-six patients had gastric cancer (all of whom were pretreated with polychemotherapy) and 24 had advanced pancreatic carcinoma. Results: Objective responses were obtained in 4 (15{\%}; 95{\%} CI 1-29) patients with gastric cancer, and in I (4{\%}) with pancreatic cancer. The median response duration was 4 months. All of the responses were seen in patients previously treated with 5-FU-containing regimens. The median survival in gastric cancer patients was 7 months. Toxicity was moderate: WHO grade III and IV diarrhea was observed in 14{\%} of the cases. Conclusions: This study indicates the efficacy of oral d-FUR plus l-leucovorin as palliative treatment in gastric cancer patients. The results in Doxifluridine pancreatic carcinoma are disappointing but are in line with the published data Chemotherapy relating to fluoropyrimidines.",
keywords = "Chemotherapy, Doxifluridine, Fluoropyrimidine, Gastric cancer, Pancreatic cancer",
author = "{Di Bartolomeo}, Maria and Emilio Bajetta and Luisa Somma and Carlo Carnaghi and Elena Bandieri and {Del Vecchio}, Michele and Stampino, {Corroda Gallo} and Roberta Buzzoni",
year = "1996",
month = "1",
language = "English",
volume = "53",
pages = "54--57",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients

AU - Di Bartolomeo, Maria

AU - Bajetta, Emilio

AU - Somma, Luisa

AU - Carnaghi, Carlo

AU - Bandieri, Elena

AU - Del Vecchio, Michele

AU - Stampino, Corroda Gallo

AU - Buzzoni, Roberta

PY - 1996/1

Y1 - 1996/1

N2 - Background: The association of 5-fluorouracil (5-FU) and leucovorin is currently the most used combination in the treatment of advanced gastrointestinal neoplasms. Doxifluridine (d-FUR) is a fluoropyrimidine derivative that is converted into 5-FU inside tumor cells, where it is selectively cytotoxic. The oral administration of dFUR has been extensively investigated in colorectal carcinoma, and has been proven to be active and well tolerated. The purpose of this study was to test the effectiveness of the oral combination with dFUR plus I-leucovorin in gastric and pancreatic cancer patients. Methods: a total of 50 cases were treated with I-leucovorin 25 mg, followed 2 h later by d-FUR 1,200 mg/m2 for 5 days; the cycles were repeated every 10 days. The regimen was given for a maximum of 36 cycles or until disease progression. Twenty-six patients had gastric cancer (all of whom were pretreated with polychemotherapy) and 24 had advanced pancreatic carcinoma. Results: Objective responses were obtained in 4 (15%; 95% CI 1-29) patients with gastric cancer, and in I (4%) with pancreatic cancer. The median response duration was 4 months. All of the responses were seen in patients previously treated with 5-FU-containing regimens. The median survival in gastric cancer patients was 7 months. Toxicity was moderate: WHO grade III and IV diarrhea was observed in 14% of the cases. Conclusions: This study indicates the efficacy of oral d-FUR plus l-leucovorin as palliative treatment in gastric cancer patients. The results in Doxifluridine pancreatic carcinoma are disappointing but are in line with the published data Chemotherapy relating to fluoropyrimidines.

AB - Background: The association of 5-fluorouracil (5-FU) and leucovorin is currently the most used combination in the treatment of advanced gastrointestinal neoplasms. Doxifluridine (d-FUR) is a fluoropyrimidine derivative that is converted into 5-FU inside tumor cells, where it is selectively cytotoxic. The oral administration of dFUR has been extensively investigated in colorectal carcinoma, and has been proven to be active and well tolerated. The purpose of this study was to test the effectiveness of the oral combination with dFUR plus I-leucovorin in gastric and pancreatic cancer patients. Methods: a total of 50 cases were treated with I-leucovorin 25 mg, followed 2 h later by d-FUR 1,200 mg/m2 for 5 days; the cycles were repeated every 10 days. The regimen was given for a maximum of 36 cycles or until disease progression. Twenty-six patients had gastric cancer (all of whom were pretreated with polychemotherapy) and 24 had advanced pancreatic carcinoma. Results: Objective responses were obtained in 4 (15%; 95% CI 1-29) patients with gastric cancer, and in I (4%) with pancreatic cancer. The median response duration was 4 months. All of the responses were seen in patients previously treated with 5-FU-containing regimens. The median survival in gastric cancer patients was 7 months. Toxicity was moderate: WHO grade III and IV diarrhea was observed in 14% of the cases. Conclusions: This study indicates the efficacy of oral d-FUR plus l-leucovorin as palliative treatment in gastric cancer patients. The results in Doxifluridine pancreatic carcinoma are disappointing but are in line with the published data Chemotherapy relating to fluoropyrimidines.

KW - Chemotherapy

KW - Doxifluridine

KW - Fluoropyrimidine

KW - Gastric cancer

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=0030025156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030025156&partnerID=8YFLogxK

M3 - Article

C2 - 8570132

AN - SCOPUS:0030025156

VL - 53

SP - 54

EP - 57

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -